E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Newly diagnosed glioblastoma (primary highly malignant brain cancer) patients Under treatment |
Patients en traitement pour un glioblastome (cancer hautement malin du cerveau) nouvellement diagnostiqué |
|
E.1.1.1 | Medical condition in easily understood language |
Newly diagnosed brain cancer patients |
Patients atteints d'un cancer du cerveau nouvellement diagnostiqué |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Phase III study comparing the standard of care radio- and temozolomide therapy for newly diagnosed glioblastoma patients (published in the literature) as compared to the same treatment adding citalopram each day 20 mg a day from the diagnosis to survival
Survival analysis |
Essai clinique de phase III comparant le standard de soin avec le même traitement accompagné d'un traitement anti-dépresseur
Evaluation de la survie |
|
E.2.2 | Secondary objectives of the trial |
Quality of live comparison knowing that the treatment of depression during cancer therapy could increase quality of live and even survival
We will be helped by a psychiatrist practician |
Analyse de la qualité de vie |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Newly diagnosed glioblastoma
Signed informed consent
Age > = 18 years |
Patients ayant un glioblastome nouvellement diagnostiqué
Patients ayant signé le formulaire d'information et de consentement
Age > = 18 ans |
|
E.4 | Principal exclusion criteria |
Recurrent glioblastoma
Citalopram related exclusion criteria
Participation in another study |
Glioblastomes en récidive
Exclusion liée au citalopram
Participation dans un autre essai clinique |
|
E.5 End points |
E.5.1 | Primary end point(s) |
could citalopram added to the standard of care increase quality of live and survival of glioblastoma patients |
Le citalopram ajouté au traitement standard des patients atteints d'un glioblastome peut-il améliorer leur survie ou leur qualité de vie? |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
quality of live |
qualité de vie |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
quality of live questionnaire (EORTC) and with a psychiatric evaluation |
questionnaire de qualité de vie utilisé par l'EORTC ainsi qu'un questionnaire spécifique mis au point par un psychiatre de notre institution |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the trial after the inclusion of 50 patients (from diagnosis to the death) |
inclusion du 50ème patient (du diagnostic de glioblastome au décès du patient) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |